Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 4/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MITF | O75030 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | RAD52 | P43351 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13520610 | 0.98 | TERT (0.57) | TERTOPRM1OPRK1TMEM97SIGMAR1 | |
| SCHEMBL3520767 | 0.88 | TERT (0.64) | TERTMEN1MITFPOLBRAD52 | |
| SCHEMBL3517478 | 0.88 | TERT (0.49) | TERTOPRM1OPRK1TMEM97SIGMAR1 | |
| SCHEMBL3293980 | 0.87 | TERT (0.49) | TERTKDM4EHDAC3HDAC4HDAC1 | |
| SCHEMBL3292099 | 0.87 | TP53 (0.61) | TERTMEN1POLBKMT2AKDM4E | |
| SCHEMBL3290737 | 0.84 | BCHE (0.46) | TERTMEN1POLBKMT2ATP53 | |
| SCHEMBL3520973 | 0.80 | TERT (0.47) | TERTMEN1POLBKMT2AKDM4E | |
| SCHEMBL13338303 | 0.80 | MEN1 (0.49) | TERTMEN1POLBKMT2AKDM4E | |
| SCHEMBL3518638 | 0.79 | TERT (0.47) | TERTMEN1POLBKMT2AKDM4E | |
| SCHEMBL29196428 | 0.78 | TERT (0.54) | TERTMEN1POLBKMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100331355-A1 | Substituted Quinolines for the Treatment of Cancer | CRYSTAX PHARMACEUTICALS, S.L. (ES) | 2010-12-30 | — | — | US | claimed |
| US-7728000-B2 | Substituted quinolines for the treatment of cancer | CRYSTAX PHARMACEUTICALS (ES) | 2010-06-01 | — | — | US | claimed |
| JP-2007511573-A | — | — | 2007-05-10 | — | — | JP | claimed |
| US-20070105784-A1 | Substituted quinolines for the treatment of cancer | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2007-05-10 | — | — | US | claimed |
| EP-1687304-A1 | SUBSTITUTED QUINOLINES FOR THE TREATMENT OF CANCER | Crystax Pharmaceuticals S.L. (ES) | 2006-08-09 | — | — | EP | claimed |
| WO-2005054236-A1 | SUBSTITUTED QUINOLINES FOR THE TREATMENT OF CANCER | CRYSTAX PHARMACEUTICALS S.L. (ES) | 2005-06-16 | — | — | WO | claimed |
| US-20100331355-A1 | Substituted Quinolines for the Treatment of Cancer | CRYSTAX PHARMACEUTICALS, S.L. (ES) | 2010-12-30 | — | — | US | disclosed |
| US-7728000-B2 | Substituted quinolines for the treatment of cancer | CRYSTAX PHARMACEUTICALS (ES) | 2010-06-01 | — | — | US | disclosed |
| US-20070105784-A1 | Substituted quinolines for the treatment of cancer | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2007-05-10 | — | — | US | disclosed |
| EP-1687304-A1 | SUBSTITUTED QUINOLINES FOR THE TREATMENT OF CANCER | Crystax Pharmaceuticals S.L. (ES) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005054236-A1 | SUBSTITUTED QUINOLINES FOR THE TREATMENT OF CANCER | CRYSTAX PHARMACEUTICALS S.L. (ES) | 2005-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105784-A1 | Substituted quinolines for the treatment of cancer | TOP2B, NQO2, SNRPD2 | TERT 1359/4885OPRM1 1978/4885OPRK1 1398/4885 |
| US-20100331355-A1 | Substituted Quinolines for the Treatment of Cancer | TOP2B, TOP1, TOP2A | TERT 1447/4885OPRM1 2039/4885OPRK1 1696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.